Copyright @ 200
American Society for Colposcopy and Cervical Pathology. Unauthorized reproduction of this article is prohibited.
2006 Consensus Guidelines for theManagement of Women WithAbnormal Cervical Screening Tests
Thomas C. Wright Jr., MD,
L. Stewart Massad, MD,
Charles J. Dunton, MD,
Mark Spitzer, MD,
Edward J. Wilkinson, MD,
and Diane Solomon, MD;
for the 2006 ASCCP-Sponsored Consensus Conference
Department of Pathology, College of Physicians and Surgeons of Columbia University,New York, NY,
Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis, MO,
Department of Obstetrics and Gynecology, Lankenau Hospital,Wynnewood, PA,
Department of Obstetrics and Gynecology, Brookdale University Hospital and Medical Center, Brooklyn, NY,
Department of Pathology, University of FloridaCollege of Medicine, Gainesville, FL, and
National Institutes of Health and National Cancer Institute, Bethesda, MD
To provide revised evidence-based consen-sus guidelines for managing women with abnormalcervical cancer screening test results.
A group of 146 experts, including repre-sentatives from 29 professional organizations, federalagencies, and national and international health organiza-tions, met in Bethesda, MD, September 18
19, 2006, todevelop the guidelines.
Major Changes in Guidelines.
The core recommenda-tions for managing women with atypical squamous cellsof undetermined significance and low-grade squamousintraepithelial lesions were changed minimally. Postcol-poscopy management for women with these cytologicalabnormalities is now identical. Management recommen-dations for these conditions did change for ‘‘specialpopulations,’’ such as adolescents for whom a more con-servative approach incorporating cytological follow-upfor 2 years was approved. Core recommendations formanaging women with high-grade squamous intra-epithelial lesions and atypical glandular cells also under-went only minor modifications. More emphasis is placedon immediate ‘‘screen-and-treat’’ approaches whenmanaging women with high-grade squamous intra-epithelial lesion. Testing for high-risk human papilloma-virus DNA is incorporated into the management ofwomen with atypical glandular cells after their initialevaluation with colposcopy and endometrial sampling.The 2004 Interim Guidance for the use of humanpapillomavirus DNA testing as an adjunct to cervicalcytology for screening in women 30 years and older wasformally adopted with only very minor modifications.
The 2006 Consensus Guidelines reflectrecent data from large clinical trials and advances intechnology and are designed to assist clinicians of allsubspecialties.
atypical squamous cells of undeterminedsignificance (ASC-US), low-grade squamous intraepitheliallesion, high-grade squamous intraepithelial lesion, cervicalcytology, human papillomavirus (HPV) testing, cervicalcancer screening
n 2001, the American Society for Colposcopy andCervical Pathology (ASCCP) joined other professional
Reprint requests to: Thomas C. Wright Jr., MD, Room 16-404, P&SBuilding, 630 W 168th St, New York, NY 10032. E-mail: firstname.lastname@example.orgThese evidenced-based consensus guidelines are designed to assistclinicians of all subspecialties in managing women with abnormal cervicalcancer screening tests. These guidelines were developed with funding fromthe American Society for Colposcopy and Cervical Pathology and theNational Cancer Institute. Its contents are solely the responsibility of theauthors and the American Society for Colposcopy and Cervical Pathologyand do not necessarily represent the official views of the National CancerInstitute.
2007, American Society for Colposcopy and Cervical Pathology
Journal of Lower Genital Tract Disease, Volume 11, Number 4, 2007, 201